Journal of Clinical Oncology, Vol 15, 1455-1464, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors

DJ Debono, DK Heilman, LH Einhorn and JP Donohue
Department of Medicine, Indiana University School of Medicine, Indianapolis, USA.

PURPOSE: This retrospective study was undertaken to assess the outcome of patients with disseminated nonseminomatous germ cell tumor (NSGCT) managed under a postchemotherapy strategy developed at Indiana University. PATIENTS AND METHODS: This is a retrospective analysis of 295 consecutive patients with disseminated NSGCT treated with primary chemotherapy at Indiana University from 1987 to 1994. The patients were placed into five groups based on response to primary chemotherapy and the presence or absence of teratoma in the primary tumor. The 295 patients were divided as follows: group A (complete remission [CR]) n = 78; group B (unresectable), n = 50; group C (serologic CR, teratoma- positive primary tumor, resectable partial remission [PR]), n = 90; group D [serologic CR, teratoma-negative primary tumor, < 90% radiographic PR], n = 50; and group E (serologic CR, teratoma-negative primary tumor, > or = 90% radiographic PR), n = 27. Groups A, B, and E patients were routinely observed after chemotherapy, whereas groups C and D patients were routinely taken to postchemotherapy surgery. RESULTS: The percent of patients who continuously had no evidence of disease (NED) were as follows: group A, 92%; group B, 40%; group C, 87%; group D, 86%; and group E, 74%. In assessing group A patients, the bulk of retroperitoneal disease at presentation had no influence on ultimate outcome. CONCLUSION: Patients with NSGCT who achieve a serologic and radiographic CR with primary chemotherapy (group A) can be safely observed without surgical intervention, regardless of initial tumor bulk. Patients with a teratoma-negative primary tumor who achieve a serologic CR and a > or = 90% radiographic remission and are followed- up without surgical resection (group E) are at an increased risk of relapsed NSGCT. Decisions about postchemotherapy resection in this group remain complicated and controversial. Options include observation with serial radiologic evaluation or surgical resection of persistent mass or masses.

This article has been cited by other articles:

				K. Oechsle, M. Hartmann, W. Brenner, S. Venz, L. Weissbach, C. Franzius, S. Kliesch, S. Mueller, S. Krege, R. Heicappell, et al. [18F]Fluorodeoxyglucose Positron Emission Tomography in Nonseminomatous Germ Cell Tumors After Chemotherapy: The German Multicenter Positron Emission Tomography Study Group J. Clin. Oncol., December 20, 2008; 26(36): 5930 - 5935. [Abstract] [Full Text] [PDF]

				A. J. Stephenson, G. J. Bosl, R. J. Motzer, D. F. Bajorin, J. P. Stasi, and J. Sheinfeld Nonrandomized Comparison of Primary Chemotherapy and Retroperitoneal Lymph Node Dissection for Clinical Stage IIA and IIB Nonseminomatous Germ Cell Testicular Cancer J. Clin. Oncol., December 10, 2007; 25(35): 5597 - 5602. [Abstract] [Full Text] [PDF]

				G. V. Kondagunta and R. J. Motzer Chemotherapy for Advanced Germ Cell Tumors J. Clin. Oncol., December 10, 2006; 24(35): 5493 - 5502. [Abstract] [Full Text] [PDF]

				G. V. Kondagunta, R. J. Motzer, G. J. Bosl, and J. Sheinfeld IN REPLY J. Clin. Oncol., June 1, 2006; 24(16): 2598 - 2599. [Full Text] [PDF]

				G. V. Kondagunta, J. Bacik, D. Bajorin, D. Dobrzynski, J. Sheinfeld, R. J. Motzer, and G. J. Bosl Etoposide and Cisplatin Chemotherapy for Metastatic Good-Risk Germ Cell Tumors J. Clin. Oncol., December 20, 2005; 23(36): 9290 - 9294. [Abstract] [Full Text] [PDF]

				B. S. Carver and J. Sheinfeld Germ Cell Tumors of the Testis Ann. Surg. Oncol., November 1, 2005; 12(11): 871 - 880. [Abstract] [Full Text] [PDF]

				H. J. Schmoll, R. Souchon, S. Krege, P. Albers, J. Beyer, C. Kollmannsberger, S. D. Fossa, N. E. Skakkebaek, R. de Wit, K. Fizazi, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG) Ann. Onc., September 1, 2004; 15(9): 1377 - 1399. [Abstract] [Full Text] [PDF]

				J. Oldenburg, G. C. Alfsen, H. H. Lien, N. Aass, H. Waehre, and S. D. Fossa Postchemotherapy Retroperitoneal Surgery Remains Necessary in Patients With Nonseminomatous Testicular Cancer and Minimal Residual Tumor Masses J. Clin. Oncol., September 1, 2003; 21(17): 3310 - 3317. [Abstract] [Full Text] [PDF]

				K. Fizazi, S. Tjulandin, R. Salvioni, J. R. Germa-Lluch, J. Bouzy, D. Ragan, C. Bokemeyer, A. Gerl, A. Flechon, J. S. de Bono, et al. Viable Malignant Cells After Primary Chemotherapy for Disseminated Nonseminomatous Germ Cell Tumors: Prognostic Factors and Role of Postsurgery Chemotherapy--Results From an International Study Group J. Clin. Oncol., May 15, 2001; 19(10): 2647 - 2657. [Abstract] [Full Text] [PDF]